MMMarcelo Dantas Tavares de Melo

Marcelo Dantas Tavares de Melo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcelo Dantas Tavares de Melo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Noonan Syndrome, Noncompaction of the Myocardium, Hypertrophic Cardiomyopathy, and Long QT Syndrome: A Case Series

    by Anna Luisa de Melo Lula Lins Pimentel, Érika Alves da Silva, Marcelo Dantas Tavares de Melo, Vera Maria Cury Salemi

    Background: The Noonan syndrome (NS) is a rare genetic disorder characterized by manifestations such as short stature, a webbed neck,

  • Open Access

    Associação da Síndrome de Noonan, Miocárdio não Compactado, Cardiomiopatia Hipertrófica e Síndrome do QT Longo: Uma Série de Casos

    by Anna Luisa de Melo Lula Lins Pimentel, Érika Alves da Silva, Marcelo Dantas Tavares de Melo, Vera Maria Cury Salemi

    Introdução: A síndrome de Noonan (SN) é uma doença genética rara caracterizada por manifestações como baixa estatura, pescoço alado, micrognatia e hipertelorismo. Embora a SN predisponha a distúrbios cardíacos, como a cardiomiopatia hipertrófica (CMH), sua associação com o miocárdio não compactado (MNC) é rara. O MNC é uma anomalia embriológica marcada por trabeculação excessiva e formação de recessos miocárdicos profundos, cuja apresentação clínica varia de assintomática a eventos tromboembólicos graves. Este estudo visa descrever as alterações e os desfechos cardiovasculares em portadores de SN e MNC acompanhados no serviço de cardiologia de um hospital brasileiro. Metodologia: Trata-se de um estudo observacional, longitudinal e prospectivo, envolvendo o acompanhamento de três pacientes adultos com fenótipo de SN. Os pacientes foram avaliados por meio de ecocardiograma e ressonância magnética cardíaca (RMC). Dados como idade, sexo, histórico familiar, início dos sintomas e desfechos, como eventos tromboembólicos, transplante cardíaco (TxC) e óbito, foram analisados. Resultados: Todos os três pacientes acompanhados (dois homens e uma mulher, irmã de um dos homens) apresentavam MNC com disfunção ventricular. A paciente do sexo feminino também apresentava síndrome do QT longo (SQTL). Todos desenvolveram trombo apical, sendo dois casos no ventrículo esquerdo (VE). A paciente do sexo feminino foi submetida a TxC, enquanto os dois homens faleceram após quadro de descompensação e evolução para choque cardiogênico. Conclusão: Este estudo ressalta a necessidade de diagnóstico precoce e triagem familiar em pacientes com SN, visando à otimização do tratamento e à melhora prognóstica. Não há registro na literatura de associação de todas as patologias descritas em um mesmo paciente.

  • Open Access

    Advances in the Treatment of Cardiac Amyloidosis

    by Ariane Vieira Scarlatelli Macedo, Pedro Vellosa Schwartzmann, Breno Moreno de Gusmão, Marcelo Dantas Tavares de Melo, Otávio Rizzi Coelho-Filho

    Opinion statement: Cardiac amyloidosis is associated with a high mortality rate, a long delay between the first signs and the diagnosis but a short interval between diagnosis and death. This scenario has changed recently due to improved disease awareness among doctors and significant progress in diagnosis thanks to multimodal imaging and a multidisciplinary approach. Therefore, during the last few years, we have had access to specific therapies for those patients. Those therapies are quite different depending on the type of amyloidosis, but there has been real progress. Systemic light chain amyloidosis (AL) with cardiac involvement is the most common form of cardiac amyloidosis. The severity of heart disease dictates the prognosis in AL amyloidosis. Advances in chemotherapy and immunotherapy that suppress light chain production have improved the outcomes. These recent improvements in survival rates have enabled therapies such as implanted cardiac defibrillators and heart transplantation that were usually not indicated for patients with advanced light chain amyloid cardiomyopathy to now be applied in selected patients. For transthyretin amyloidosis (ATTR), the second most common form of amyloidosis with cardiac involvement, there is also significant progress in treatment. Until recently, we had no specific therapy for ATTR cardiomyopathy (ATTR-CM), though now disease-modifying therapies are available. Therapies that stabilize transthyretin, such as tafamidis, have been shown to improve outcomes for patients with ATTR-CM. Modern treatments that stop the synthesis of TTR through gene silencing, such as patisiran and inotersen, have shown positive results for patients with TTR amyloidosis. Significant progress has been made in the treatment of amyloid cardiomyopathy, and hopefully, we will see even more progress with the spread of those treatments. We now can be optimistic about patients with this disease.


  • Open Access

    Noncompaction cardiomyopathy: a substrate for a thromboembolic event

    by Marcelo Dantas Tavares de Melo, José Arimateia Batista de Araújo Filho, Camila Rocon de Lima, Charles Mady, Roberto Kalil-Filho, Vera Maria Cury Salemi

    Noncompaction cardiomyopathy (NCC) is a rare genetic cardiomyopathy characterized by a thin, compacted epicardial layer and an extensive noncompacted endocardial layer. The clinical manifestations of this disease include ventricular arrhythmia, heart failure, and systemic thromboembolism. A 43-year-old male was anticoagulated by pulmonary thromboembolism for 1 year when he developed progressive dyspnea. Cardiovascular magnetic resonance imaging showed severe biventricular trabeculation with an ejection fraction of 15%, ratio of maximum noncompacted/compacted diastolic myocardial thickness of 3.2 and the presence of exuberant biventricular apical thrombus. Still under discussion is the issue of which patients and when they should be anticoagulated. It is generally recommended to those presenting ventricular systolic dysfunction, antecedent of systemic embolism, presence of cardiac thrombus and atrial fibrillation. In clinical practice the patients with NCC and ventricular dysfunction have been given oral anticoagulation, although there are no clinical trials showing the real safety and benefit of this treatment.


  • Left ventricular basal region involvement in noncompaction cardiomyopathy

    by Marcelo Dantas Tavares de Melo, Luiz A. Benvenuti, Charles Mady, Roberto Kalil-Filho, Vera MC Salemi